Gastroenterology · Metabolic Dysfunction-Associated Steatotic Liver Disease
The facts most likely to be tested
Nonalcoholic fatty liver disease is strongly associated with metabolic syndrome, specifically obesity, type 2 diabetes mellitus, and hypertriglyceridemia.
The gold standard for definitive diagnosis and staging of nonalcoholic steatohepatitis (NASH) remains a liver biopsy showing steatosis, ballooning degeneration, and Mallory-Denk bodies.
Patients typically present with asymptomatic elevation of ALT and AST in a ratio of < 1, distinguishing it from the AST:ALT > 2:1 ratio seen in alcoholic liver disease.
First-line management for all patients is lifestyle modification focusing on weight loss through caloric restriction and physical activity.
Pioglitazone or GLP-1 receptor agonists (e.g., semaglutide) are the preferred pharmacologic agents for patients with biopsy-proven NASH and comorbid type 2 diabetes.
Non-invasive testing such as the NAFLD fibrosis score or transient elastography (FibroScan) is used to screen for advanced fibrosis or cirrhosis.
Patients with NAFLD are at increased risk for hepatocellular carcinoma (HCC), even in the absence of established cirrhosis.
Vignette unlocked
A 52-year-old male with a history of type 2 diabetes and obesity presents for a routine follow-up. Physical examination reveals a BMI of 34 kg/m² and mild hepatomegaly. Laboratory studies show an ALT of 88 U/L and an AST of 52 U/L. A liver ultrasound demonstrates increased echogenicity consistent with hepatic steatosis. The patient denies alcohol use and viral hepatitis serologies are negative.
What is the most appropriate initial management for this patient?
Lifestyle modification with weight loss
The patient presents with classic features of NAFLD; the first-line treatment for all patients, regardless of severity, is lifestyle modification to achieve weight loss, which is the only intervention proven to improve both steatosis and fibrosis.
Full handout
High yield triage
Etiology / Epidemiology
Strongly associated with metabolic syndrome, obesity, and type 2 diabetes. Often termed the hepatic manifestation of insulin resistance.
Clinical Manifestations
Usually asymptomatic; may present with hepatomegaly or RUQ discomfort. Elevated ALT > AST is the classic biochemical pattern.
Diagnosis
Liver biopsy is the gold standard. FibroScan (transient elastography) is the preferred non-invasive screening tool.
Treatment
Weight loss (7-10%) is the primary intervention. Pioglitazone or Vitamin E are indicated for biopsy-proven NASH.
Prognosis
Risk of progression to cirrhosis and hepatocellular carcinoma. Monitor for decompensated liver failure.
Full handout
Epidemiology & Etiology
NAFLD is the most common cause of chronic liver disease in developed nations. It is driven by insulin resistance leading to increased free fatty acid flux to the liver. Patients typically present with obesity, dyslipidemia, and hypertension.
Pertinent Anatomy
Fat accumulation occurs primarily in the hepatocytes (steatosis). Chronic inflammation leads to perisinusoidal fibrosis, often described as a chicken-wire pattern on histology.
Pathophysiology
Excessive caloric intake overwhelms hepatic lipid metabolism, causing triglyceride accumulation. This triggers oxidative stress and cytokine release, progressing from simple steatosis to nonalcoholic steatohepatitis (NASH). Persistent inflammation activates stellate cells, resulting in irreversible fibrosis.
Clinical Manifestations
Most patients are asymptomatic, identified incidentally by elevated transaminases. Physical exam may reveal hepatomegaly or signs of advanced disease like spider angiomata. Red flags include jaundice, ascites, or encephalopathy, indicating progression to cirrhosis.
Diagnosis
Diagnosis requires evidence of hepatic steatosis via imaging or biopsy and exclusion of secondary causes (e.g., alcohol, medications). Liver biopsy remains the gold standard to distinguish simple steatosis from NASH. FibroScan is used to quantify liver stiffness and assess fibrosis stage.
Treatment
The cornerstone of therapy is lifestyle modification focusing on diet and exercise to achieve 7-10% weight loss. Pioglitazone is used in patients with biopsy-proven NASH, though weight gain is a common side effect. Vitamin E (800 IU/day) is an alternative for non-diabetic patients, but prostate cancer risk must be considered.
Prognosis
Patients with NASH are at significant risk for cirrhosis and hepatocellular carcinoma (HCC). Surveillance for HCC via ultrasound every 6 months is required for patients with advanced fibrosis or cirrhosis.
Differential Diagnosis
Alcoholic Liver Disease: AST:ALT ratio > 2:1
Hepatitis C: Positive HCV antibody/RNA
Hemochromatosis: Elevated ferritin and transferrin saturation
Wilson Disease: Low ceruloplasmin and Kayser-Fleischer rings
Autoimmune Hepatitis: Elevated ANA, ASMA, and IgG levels